NCT05277922View on ClinicalTrials.gov

Effect of C21 on Forearm Blood Flow

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

May 11, 2022

Study Completion Date

May 18, 2022

Conditions
Study Vasodilatory Effects of C21
Interventions
DRUG

C21

C21 in ascending doses of 15, 50, 150, 500 and 1000 µg

DRUG

Sodium Nitroprusside

Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control

Trial Locations (1)

75237

Clinical Trial Consultants AB, Uppsala

Sponsors
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Vicore Pharma AB

INDUSTRY